Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Cost analysis of adverse events associated with non-small cell lung cancer management in France.

Chouaid C, Loirat D, Clay E, Millier A, Godard C, Fannan A, Lévy-Bachelot L, Angevin E.

Clinicoecon Outcomes Res. 2017 Jul 27;9:443-449. doi: 10.2147/CEOR.S138963. eCollection 2017.


Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.

Jamotte A, Clay E, Macabeo B, Caicedo A, Lopez JG, Bricks L, Romero Prada M, Marrugo R, Alfonso P, Moreno Arévalo B, Franco D, Garcia Diaz L, Isaza de Molto Y.

Hum Vaccin Immunother. 2017 Apr 3;13(4):877-888. doi: 10.1080/21645515.2016.1256928. Epub 2017 Jan 24.


The quality of life of Spanish patients with Huntington's disease measured with H-QoL-I and EQ-5D.

Dorey J, Clay E, Khemiri A, Belhadj A, Cubillo PT, Toumi M.

J Mark Access Health Policy. 2016 Oct 13;4. doi: 10.3402/jmahp.v4.27356. eCollection 2016.


Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.

Uhart M, Bricout H, Clay E, Largeron N.

Hum Vaccin Immunother. 2016 Sep;12(9):2259-68. doi: 10.1080/21645515.2016.1180490. Epub 2016 May 11.


Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model.

Hu S, Yu X, Chen S, Clay E, Toumi M, Milea D.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):565-78. doi: 10.1586/14737167.2015.1065734.


Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States.

Asche CV, Clay E, Kharitonova E, Zah V, Ruby J, Aballéa S.

J Med Econ. 2015;18(8):600-11. doi: 10.3111/13696998.2015.1036760. Epub 2015 May 20.


Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.

Clay E, Khemiri A, Zah V, Aballéa S, Ruby J, Asche CV.

J Med Econ. 2014 Sep;17(9):626-36. doi: 10.3111/13696998.2014.925463. Epub 2014 Jun 6.


A clinical research practice datalink analysis of antidepressant treatment patterns and health care costs in generalized anxiety disorder.

Chollet J, Saragoussi D, Clay E, François C.

Value Health. 2013 Dec;16(8):1133-9. doi: 10.1016/j.jval.2013.09.001. Epub 2013 Oct 20.


Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France.

Guelfucci F, Clay E, Aballéa S, Lassalle R, Moore N, Toumi M.

BMC Endocr Disord. 2013 Apr 29;13:15. doi: 10.1186/1472-6823-13-15.


Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries.

Clay E, Falissard B, Moore N, Toumi M.

Eur J Clin Pharmacol. 2013 Apr;69(4):1-10. doi: 10.1007/s00228-012-1424-1. Epub 2012 Nov 1.


Further evidence of reliability and validity of the Huntington's disease quality of life battery for carers: Italian and French translations.

Aubeeluck A, Dorey J, Squitieri F, Clay E, Stupple EJ, De Nicola A, Buchanan H, Martino T, Toumi M.

Qual Life Res. 2013 Jun;22(5):1093-8. doi: 10.1007/s11136-012-0227-2. Epub 2012 Jul 21.


Validation of the first quality-of-life measurement for patients with Huntington's disease: the Huntington Quality of Life Instrument.

Clay E, De Nicola A, Dorey J, Squitieri F, Aballéa S, Martino T, Tedroff J, Zielonka D, Auquier P, Verny C, Toumi M.

Int Clin Psychopharmacol. 2012 Jul;27(4):208-14. doi: 10.1097/YIC.0b013e3283534fa9.


Supplemental Content

Loading ...
Support Center